Apex Biotechnology Corp. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 484.485 million compared to TWD 529.084 million a year ago. Operating income was TWD 37.314 million compared to TWD 32.042 million a year ago. Net income was TWD 22.471 million compared to TWD 26.760 million a year ago. Basic earnings per share from continuing operations was TWD 0.23 compared to TWD 0.27 a year ago. Diluted earnings per share from continuing operations was TWD 0.21 compared to TWD 0.25 a year ago. For the half year, sales was TWD 1,060.873 million compared to TWD 1,041.014 million a year ago. Operating income was TWD 99.584 million compared to TWD 47.129 million a year ago. Net income was TWD 56.632 million compared to TWD 38.728 million a year ago. Basic earnings per share from continuing operations was TWD 0.57 compared to TWD 0.39 a year ago. Diluted earnings per share from continuing operations was TWD 0.53 compared to TWD 0.36 a year ago.